Biocom Partnering Conference: Pharma, VCs Hungry For Deals, But Good Assets Hard To Find
Pharma business development executives, venture capital investors and small life science companies came together at Biocom's Global Life Science Partnering Conference in San Diego to talk about deal-making and financing.
You may also be interested in...
Celgene is known among biotechnology firms for being a disciplined buyer and an ideal collaborator – a reputation in which the company's head dealmaker George Golumbeski takes a lot of pride.
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.